Navigation Links
Latest findings of Dartmouth HIV/AIDS study could turn treatment 'on its head'
Date:3/3/2011

LEBANON, NH - A clinical study of anti-HIV/AIDS medicines in the developing world is on the verge of turning "the whole treatment world on its head," according to Dartmouth pediatrician Paul Palumbo.

Palumbo, a professor of pediatric medicine at Dartmouth Medical School and executive director of the Dartmouth-affiliated DarDar Pediatric program in Dar-es-Salaam, Tanzania, unveiled the latest findings of the International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT ) during the 2011 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston from February 27-March 2.

Before making a formal, "late-breaking" presentation about IMPAACT's findings in Africa and India to fellow clinicians and researchers at CROI, Palumbo also shared, under confidentiality restrictions, the revelations with representatives of the World Health Organization (WHO) and of a working group of pharmaceutical leaders and officials of the U.S. State Department.

The IMPAACT P1060 trials comparing the effects of different forms of treatment on infants and young mothers began in 2006, with support from the National Institute of Allergy and Infectious Disease (NIAID) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). On October 27, 2010, an independent data and safety monitoring board (DSMB), which confidentially reviews large clinical trials on an interim basis for safety and efficacy of drugs, halted the second phase of P1060, declaring that the protease inhibitor lopinavir (LPV/r) was working so well among infants with no previous exposure to the popular anti-retroviral nevirapine (NVP) that the IMPAACT team didn't need to go further in the head-to-head trials between LPV/r and NVP to prove their point.

"We were a little surprised, anticipating the trial would run to March of 2011," Palumbo says. "We didn't expect such a superior difference."

This was the second time that IMPAACT, which Palumbo serves as a vice chair, turned heads: In the spring of 2009, the DSMB halted the first phase of the P1060 trial involving 164 HIV-infected children ages 6 to 35 months, after learning that a cohort of 82 youngsters responded better to treatment with LPV/r than did a cohort of 82 children in the same age group who had received NVP [http://www.niaid.nih.gov/news/newsreleases/2009/pages/p1060.aspx].

The difference from the current study cohort was that all 164 children in the first-phase cohort had previously received a single dose of NVP in liquid form at birth, and their mothers had taken NVP in the form of a single pill during labor in an effort to prevent transmission of HIV. When these children, who were HIV-infected despite efforts to prevent mother-to-child transmission, later required HIV treatment, they were enrolled into the P1060 trial and randomly assigned to therapy with the antiretroviral drugs Zidovudine and Lamivudine, plus either NVP or LPV/r the latter also known as Kaletra.-- The treatment with LPV/r proved superior enough for WHO to recommend that infants with HIV infection and exposure to NVP at birth start on an LPV/r-based regimen whenever possible.

The DSMB then gave IMPAACT the go-ahead to continue to enroll children who did not receive NVP at birth into the second-phase cohort. And in October of 2010, a couple of weeks before the DSMB halted the second phase, the New England Journal of Medicine (NEJM) published IMPAACT's first-phase study results [http://www.nejm.org/doi/full/10.1056/NEJMoa1000931]. In an editorial accompanying the NEJM study, authors Marc Lallemant, M.D., and Gonzague Jourdain, M.D., praise the IMPAACT findings and those of a trial with HIV-infected mothers that another group of researchers conducted.

"These studies help equip us with strategies to deal with the current imperfections in our scale-up efforts," the authors write. "With new WHO guidelines calling for increased access to therapy and prophylaxis the goal of eradicating pediatric HIV is within sight."

Within distant sight, Palumbo cautions, especially in sub-Saharan Africa and India.

"Nevirapine is relatively cheap to produce and distribute," Palumbo says. "Kaletra (LPV/r) is four times more expensive, and it needs a little help because it doesn't do well in high-temperature environments without much refrigeration. Much of the world is used to having access to something inexpensive. [The Kaletra findings] turned things upside-down."

Those and other facts underscore a continuing quandary for clinicians and researchers working with patients in "resource-limited countries," Palumbo says prevention versus treatment. The NVP regimen needed nearly a decade to gain acceptance. "We're left with what to do in the real world," Palumbo says. "We're back to the WHO. It's been very slow getting this off the ground."


'/>"/>

Contact: David A. Corriveau
david.a.corriveau@Hitchcock.org
603-653-1978
Dartmouth-Hitchcock Medical Center
Source:Eurekalert

Related medicine news :

1. Groundbreaking Principal and Contributor on Dr. Oz Show Releases His Latest Book on How We Can Influence the Lives of Children
2. New York and Connecticut Drug Rehab Center Mountainside Weighs In on Latest White House Budget
3. The Future of Cosmetic Dermatology: Leading Dermatologist Dr. David Goldberg Discusses the Latest Facial Rejuvenation Techniques
4. Doctors Applaud Latest Furlough Reversal
5. Latest quality and purity specifications for food ingredients help protect consumers
6. New Study Tunes Into Latest Lipo Technique
7. Intellimed's Popular Data Reporting Software IM-IC (Intelligent Client) Receives Latest Update
8. Tampa Bay Vein Treatment and Cosmetic Dermatology Practice Using New Laser Technology Some Say is the Latest Breakthrough
9. Latest Cancer Clinic Closure in Selma, Alabama
10. New Free Webinars Announced to Discuss the Latest Federal Court Overpayment Lawsuit Ruling and New Obama Health Laws for the Skyrocketing $6 Trillion Overpayment Recoupment Market
11. Latest Resource From Dynamic Disc Designs Helps Physicians Educate Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... ... proud to announce it has added CXC Solutions (CXC) as a new Strategic ... These solutions are tailored to help benefits advisors reduce operating costs and generate ...
(Date:12/6/2016)... Pittsburgh, PA (PRWEB) , ... December 06, 2016 ... ... particle identification and characterization laboratories, is now offering HIAC particle counting and sizing ... available immediately. , Gateway Analytical instituted the new service as a response to ...
(Date:12/6/2016)... ... December 06, 2016 , ... GrekTek LLC, ... crowd funding campaign ( http://kck.st/2g3a1so ) for the HealthyWatch, a new device to ... an EKG from the watch while sharing these events with caregivers in real ...
(Date:12/6/2016)... ... ... Keeping Gift Season Safe, In a season stacked with gift-giving opportunities, it's ... recipients. This is the idea behind Safe Toys and Gifts Month, which sets aside ... good gifts for children. For companies that produce goods that fall into this category, ...
(Date:12/6/2016)... Park, KS (PRWEB) , ... December 06, 2016 , ... ... retailers of Mobility Scooters . , Mobility Scooters give freedom to people who ... balance problems. Still others may be facing a long period of rehabilitation after an ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... 2016   TrainerMD , the first HIPAA compliant software collaboration ... with Styku . Styku, a California ... to provide users world-class, real-time 3D body scanning and analysis. Together ... to see, hear and feel their health like never before. ... , , ...
(Date:12/5/2016)... 2016  CVS Health, the nation,s largest pharmacy innovation ... score of 100 percent on the Corporate Equality Index ... an annual national benchmarking survey and report on corporate ... the Human Rights Campaign Foundation. "Our ... colleagues, customers and suppliers bring to CVS Health," said ...
(Date:12/5/2016)... 5, 2016  New research by the CVS ... and the U.S. Department of Health and Human ... and Response (ASPR), published online today in ... notifications encourage patients with chronic conditions to refill ... study also affirms that public-private partnerships can facilitate ...
Breaking Medicine Technology: